TGF-β1-Licensed Murine MSCs Show Superior Therapeutic Efficacy in Modulating Corneal Allograft Immune Rejection In Vivo

Mesenchymal stromal cells (MSCs) are a promising therapeutic option for multiple immune diseases/disorders; however, efficacy of MSC treatments can vary significantly. We present a novel licensing strategy to improve the immunosuppressive capacity of MSCs. Licensing murine MSCs with transforming gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynch, Kevin, Treacy, Oliver, Chen, Xizhe, Murphy, Nick, Lohan, Paul, Islam, Md Nahidul, Donohoe, Ellen, Griffin, Matthew D., Watson, Luke, McLoughlin, Steven, O’Malley, Grace, Ryan, Aideen E., Ritter, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474271/
https://www.ncbi.nlm.nih.gov/pubmed/32531237
http://dx.doi.org/10.1016/j.ymthe.2020.05.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474271/
https://www.ncbi.nlm.nih.gov/pubmed/32531237
http://dx.doi.org/10.1016/j.ymthe.2020.05.023

Ejemplares similares